Federal policy advocacy · November 3, 2026

The American Medical Association is urging the Food and Drug Administration to maintain rigorous safety and effectiveness standards for botanical drug products, including cannabis. In an October 28 letter announced October 30, the physicians’ organization argued that popularity, personal testimonials, and commercial pressure should not replace clinical evidence.

Support for research—not a new FDA rule

AMA also supports well-controlled cannabis research to investigate possible medical uses and short- and long-term risks. Its position calls for clinical trials, appropriate research safeguards, and safety monitoring rather than bypassing the drug-approval process.

This is advocacy by a professional organization. It is not a new FDA prohibition, an enacted law, a clinical trial, or a change to Georgia’s medical-cannabis program. The statement discusses several botanical substances; warnings about that broad category should not be presented as cannabis-specific estimates of harm.

What patients and caregivers can take from this

A product being described as natural does not establish that it is safe or effective. When evaluating a treatment claim, distinguish personal experience from research findings and ask whether the evidence concerns the same product, condition, and patient population. Discuss treatment decisions and medication interactions with a qualified clinician.

Sources and context

• AMA’s October 30 announcement and link to its FDA letter ↗
• Tom Angell’s November 2 reporting ↗

Selected from The Green Peach’s November 3 intelligence report. The underlying letter, announcement, and news coverage have different dates, identified above. For education, not personalized medical or legal advice.